about
JAZF1/SUZ12 gene fusion in endometrial stromal sarcomasCDH1 is essential for endometrial differentiation, gland development, and adult function in the mouse uterusMolecular cues on obesity signals, tumor markers and endometrial cancer.A phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies.Progesterone: the ultimate endometrial tumor suppressor.Loss of CDH1 and Pten accelerates cellular invasiveness and angiogenesis in the mouse uterus.Cell-autonomous activation of the PI3-kinase pathway initiates endometrial cancer from adult uterine epithelium.Enhancer of zeste homolog 2 is involved in the proliferation of endometrial carcinoma.Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles.Progesterone action in breast, uterine, and ovarian cancers.PTEN Expression as a Predictor of Response to Focal Adhesion Kinase Inhibition in Uterine Cancer.Loss of Cdh1 and Trp53 in the uterus induces chronic inflammation with modification of tumor microenvironmentPrediction model for regional or distant recurrence in endometrial cancer based on classical pathological and immunological parametersWhole-Genome DNA Methylation Profiling Identifies Epigenetic Signatures of Uterine CarcinosarcomaImmunohistochemical characterisation of molecular subtypes in endometrial cancer.Determination of CA-125 levels in the serum, cervical and vaginal secretions, and endometrium in Chinese women with precancerous disease or endometrial cancerEndometrial cancer risk factors by 2 main histologic subtypes: the NIH-AARP Diet and Health Study.Personalized care in uterine cancer.Growth of poorly differentiated endometrial carcinoma is inhibited by combined action of medroxyprogesterone acetate and the Ras inhibitor Salirasib.The Genomic Heterogeneity of FIGO Grade 3 Endometrioid Carcinoma Impacts Diagnostic Accuracy and ReproducibilityLoss of ARID1A expression correlates with stages of tumor progression in uterine endometrioid carcinomaMitochondrial ribosomal protein S18-2 is highly expressed in endometrial cancers along with free E2F1.Gynecologic biopsy for molecular profiling: a review for the interventional radiologistEvaluation of expression of the PTEN gene, oestrogen and progesterone receptors as diagnostic and predictive factors in endometrial cancer.PCOS and obesity: insulin resistance might be a common etiology for the development of type I endometrial carcinoma.Use of mutation profiles to refine the classification of endometrial carcinomas.Identification of distinct molecular subtypes of uterine carcinosarcomaRecent and current Phase II clinical trials in endometrial cancer: review of the state of art.The Significance of the Sulfatase Pathway for Local Estrogen Formation in Endometrial CancerDNMT inhibitors and HDAC inhibitors regulate E-cadherin and Bcl-2 expression in endometrial carcinoma in vitro and in vivo.CTNNB1 (beta-catenin) mutation identifies low grade, early stage endometrial cancer patients at increased risk of recurrence.Distinct molecular subtypes of uterine leiomyosarcoma respond differently to chemotherapy treatment.Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas.Cytological nuclear atypia classification can predict prognosis in patients with endometrial cancer.L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation.Mutation status coupled with RNA-sequencing data can efficiently identify important non-significantly mutated genes serving as diagnostic biomarkers of endometrial cancer.
P2860
Q28073462-709B9253-5288-4F1B-912D-F50355DD807CQ28585530-017C3ED1-D556-4548-BB04-6A4C6B908F13Q30372789-6554FC37-30BA-4239-BB67-2FD1CDA14657Q33397006-B33FEB48-10C3-4403-A769-9B1029D61A90Q33773307-CDBD49B1-A12F-45CF-AD4F-EDCA91023B75Q33826091-36BBF9BE-9758-4E25-83B4-70D95EF9D4C1Q34182662-86614E4E-9E8B-4223-BBAA-919E838D15E3Q34293217-488B2DF4-A776-4876-93E7-9826658BA35AQ34350701-B83B6394-BB66-43B9-A687-ABB7F50590A3Q35108906-1874B175-8B47-45D0-B7F8-B305AA12A144Q35691011-0548F20E-B1A5-402A-B179-EFF29483575CQ36000984-0E932B6C-BEB0-4A86-8F1B-02C9317B36CCQ36027067-9387D2DF-267A-4A29-9783-F1496FE83712Q36249984-AF4758EB-C179-4D50-9FEA-A6E58B73FBC5Q36493409-296F805E-1894-4729-AD6A-920E848F66D3Q36516283-D71F4995-C234-48DA-B466-7D502AF14376Q36661765-3D59B6D5-1C7D-457D-9AE3-0BD78619849FQ37006856-67CB7731-65C6-4812-837E-D2BA9D8388C1Q37016586-ECBCE08F-B917-493D-9ADF-DDD54BDE0548Q37068930-0276ABA0-4FD7-4B8C-9D54-A34816128157Q37208036-FCF79B4F-4CFE-42F3-ACCF-8A8712DB7E17Q37225495-4C61CFA9-699E-4FFB-8CBE-2045890CFE59Q37329840-2E2CB002-FD38-4135-A4F4-2494E1C27969Q37471173-EDB367D9-F573-4CB7-9E3F-FF16D7D16E13Q37516309-4B88690D-0839-4482-838A-EEB6272BA441Q37612253-65983A94-4B4E-4909-BAF2-32F59C7B2E10Q37716634-7A4BC5C3-1E2F-49F0-A7D6-1CBCD87F4610Q38203354-991D75BC-84A7-4BA9-821A-3500A607845CQ38687447-25FEB7EF-14D0-427D-9D43-50381BAEA2FCQ39395099-75616291-9812-4B87-A565-76C74DA7FB27Q40986278-E8E93459-563C-4E1C-8AB0-B7392890DB16Q41279692-7C4F90D6-4C85-40D7-B5AB-9D35532D9C48Q42816041-3D6AB429-43AB-4FF2-927B-B2189F4D8E7AQ44155114-86A2FBB8-A356-4CC2-98B9-9682461845F0Q45959051-15ECABF9-D325-4FB5-865F-B313EE80BC8AQ47131591-D834A2BE-4019-4264-999F-5B61CAE12965
P2860
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Molecular profiling of endometrial malignancies.
@ast
Molecular profiling of endometrial malignancies.
@en
type
label
Molecular profiling of endometrial malignancies.
@ast
Molecular profiling of endometrial malignancies.
@en
prefLabel
Molecular profiling of endometrial malignancies.
@ast
Molecular profiling of endometrial malignancies.
@en
P2093
P2860
P356
P1476
Molecular profiling of endometrial malignancies.
@en
P2093
I-Tien Yeh
Kevin Hall
Norasate Samarnthai
P2860
P304
P356
10.1155/2010/162363
P577
2010-03-28T00:00:00Z